Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser.
Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser.
复制标题
将组织纤溶酶原激活剂转化为酶原：Asp-His-Ser 的调节三联体。
作者：
E. Madison;A. Kobe;M. Gething;J. Sambrook;E. Goldsmith
与胰凝乳蛋白酶家族的大多数丝氨酸蛋白酶不同，组织型纤溶酶原激活剂 (tPA) 作为活性单链酶从细胞中分泌，其催化效率仅略低于蛋白水解形式。 tPA 的酶原突变体已被设计成单链形式的催化效率降低了 141 倍，而裂解形式的催化效率却保留了全部活性。突变体中引入的残基，丝氨酸292和组氨酸305，被认为与天冬氨酸477形成氢键网络，类似于发现稳定酶原糜蛋白酶原的天冬氨酸194-组氨酸40-丝氨酸32网络。
Unlike most serine proteases of the chymotrypsin family, tissue-type plasminogen activator (tPA) is secreted from cells as an active, single-chain enzyme with a catalytic efficiency only slightly lower than that of the proteolytically cleaved form. A zymogenic mutant of tPA has been engineered that displays a reduction in catalytic efficiency by a factor of 141 in the single-chain form while retaining full activity in the cleaved form. The residues introduced in the mutant, serine 292 and histidine 305, are proposed to form a hydrogen-bonded network with aspartate 477, similar to the aspartate 194-histidine 40-serine 32 network found to stabilize the zymogen chymotrypsinogen.
人类哈格曼因子（因子 XII）的活化形式和酶原形式的酶活性。
影响因子：
20.3
作者：
Silverberg,M;Kaplan,AP
通讯作者：
Kaplan,AP
与使用静脉组织纤溶酶原激活剂治疗急性心肌梗死相关的出血并发症。
DOI：
10.1016/0002-9343(88)90586-4
发表时间：
1988
期刊：
The American journal of medicine
影响因子：
--
作者：
Califf,RM;Topol,EJ;George,BS;Boswick,JM;Abbottsmith,C;Sigmon,KN;Candela,R;Masek,R;Kereiakes,D;O'Neill,WW
通讯作者：
O'Neill,WW